Form 4: Virios Therapeutics Director Acquires Stock Options

Richard James Whitley, a director of Virios Therapeutics, acquired stock options to purchase 4,000 shares of common stock on February 26, 2024.

Summary

• On February 26, 2024, Richard James Whitley, a director of Virios Therapeutics, acquired stock options.
• These options allow him to purchase 4,000 shares of Virios Therapeutics common stock at an exercise price of $0.357 per share.
• The stock options vest 100% on February 26, 2025, one year after the grant date.
• Following the transaction, Whitley directly owns 4,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this is a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Virios Therapeutics, Stock Options, Director, VIRI, Beneficial Ownership, Form 4, Richard James Whitley